EP3457135A1 — Treatment options for fabry disease
Assigned to Amicus Therapeutics Inc · Expires 2019-03-20 · 7y expired
What this patent protects
A formulation for use in the treatment of Fabry disease, wherein the formulation comprises a carrier and 1-deoxygalactonojirimycin or a salt therof, characterized in that the 1-deoxygalactonojirimycin or a salt thereof is administered to a Fabry disease patient in an amount of 15…
USPTO Abstract
A formulation for use in the treatment of Fabry disease, wherein the formulation comprises a carrier and 1-deoxygalactonojirimycin or a salt therof, characterized in that the 1-deoxygalactonojirimycin or a salt thereof is administered to a Fabry disease patient in an amount of 150 mg every other day,
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.